DYNAVAX TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-11-12: Form 8-K; Period of report 2015-11-12; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2015-11-05: Form 8-K; Period of report 2015-11-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-10-08: Form 8-K; Period of report 2015-10-08; Description 8.01 Other Events; Details 8.01.
- 2015-09-15: Form 8-K; Period of report 2015-09-15; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-11-12 | 8-K | 2015-11-12 | 1.01 Entry into a Material Definitive Agreement | 1.01 On November 12, 2015, Dynavax Technologies Corporation (“Dynavax” or the “Company”) entered into an at the market issuance Sales Agreement (the “Agreement”) with Cowen and Company, LLC (“Cowen”) under which Dynavax may offer and sell from time to time at its sole discretion shares of its common stock having an aggregate offering price of up to $90,000,000 through Cowen as its sales agent. | dvax-8k_20151112.htm |
| 2015-11-05 | 8-K | 2015-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2015, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the quarter ended September 30, 2015. | dvax-8k_20151105.htm |
| 2015-10-08 | 8-K | 2015-10-08 | 8.01 Other Events | 8.01 On October 8, 2015, Dynavax Technologies Corporation issued a press release titled "Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination with Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab)." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | dvax-8k_20151008.htm |
| 2015-09-15 | 8-K | 2015-09-15 | 8.01 Other Events | 8.01 On September 15, 2015, Dynavax Technologies Corporation (the “Company”) prepaid all outstanding amounts under the Loan and Security Agreement dated as of December 23, 2014 (the “Loan Agreement) with Hercules Technology Growth Capital, Inc. (“Hercules”), at which time the Company's obligations under the Loan Agreement terminated. | dvax-8k_20150915.htm |
| 2015-08-07 | 8-K | 2015-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2015, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the quarter ended June 30, 2015. | dvax-8k_20150807.htm |
| 2015-07-22 | 8-K | 2015-07-21 | 1.01 Entry into a Material Definitive Agreement | 1.01 On July 21, 2015, Dynavax Technologies Corporation (the “Company”, “Dynavax” or “we”) entered into an underwriting agreement (“Underwriting Agreement”) with Cowen and Company, LLC as representative of the underwriters named therein (the “Underwriters”) relating to the issuance and sale of 4,545,455 shares of our common stock, at a price to the public of $27.50 per share. | d56615d8k.htm |
| 2015-07-09 | 8-K | 2015-07-09 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 Dynavax Technologies Corporation (the “Company”, “Dynavax” or “we”) estimates that its cash, cash equivalents and marketable securities were approximately $93.4 million as of June 30, 2015. 8.01 On July 9, 2015, we issued a press release titled “Dynavax Announces Third Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B™ and Updates Financial Status." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | dvax-8k_20150709.htm |
| 2015-06-01 | 8-K | 2015-06-01 | 8.01 Other Events | 8.01 On June 1, 2015, we issued a press release titled "Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | dvax-8k_20150601.htm |
| 2015-05-28 | 8-K | 2015-05-27 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 27, 2015, Dynavax Technologies Corporation (the “Company”) held its 2015 Annual Meeting of Stockholders (the “Annual Meeting”), at the Company's executive office in Berkeley, California. | dvax-8k_20150528.htm |
| 2015-05-07 | 8-K | 2015-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2015, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the quarter ended March 31, 2015. | dvax-8k_20150507.htm |
| 2015-03-05 | 8-K | 2015-03-05 | 2.02 Results of Operations and Financial Condition | 2.02 On March 5, 2015, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the year ended December 31, 2014. | dvax-8k_20150305.htm |
| 2015-03-02 | 8-K | 2015-03-02 | 8.01 Other Events | 8.01 On March 2, 2015, we issued a press release titled "Dynavax Announces Second Independent DSMB Recommendation to Continue Phase 3 Study of Heplisav-BTM." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | dvax-8k_20150302.htm |
| 2015-02-11 | 8-K | 2015-02-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Denise M. Gilbert, Ph.D., will retire from the Board of Directors (the “Board”) of Dynavax Technologies Corporation (“Dynavax” or the “Company”), following the Company’s Audit Committee meeting presently scheduled to be held on February 26, 2015. | dvax-8k_20150205.htm |
| 2015-01-09 | 8-K | 2015-01-09 | 2.02 Results of Operations and Financial Condition | 2.02 We estimate that our cash, cash equivalents and marketable securities were approximately $122.6 million as of December 31, 2014. | dvax-8k_20150109.htm |